{
    "clinical_study": {
        "@rank": "144757", 
        "arm_group": [
            {
                "arm_group_label": "Abametapir Lotion 0.74% w/w", 
                "arm_group_type": "Active Comparator", 
                "description": "Topically administered to hair and scalp for 10 minutes application."
            }, 
            {
                "arm_group_label": "Vehicle Lotion", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Administered to scalp and hair for 10 minutes application."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of the study is to evaluate ovicidal efficacy of a single application of\n      abametapir lotion 0.74% w/w intended for the treatment of head lice."
        }, 
        "brief_title": "Ovicidal Efficacy and Safety of Abametapir Lotion 0.74% Administered for the Treatment of Head Lice Infestation", 
        "condition": "Head Lice Infestation", 
        "condition_browse": {
            "mesh_term": [
                "Parasitic Diseases", 
                "Mite Infestations", 
                "Lice Infestations"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Healthy male or female based on medical history\n\n          2. Six months of age or older.\n\n          3. Has an active head lice infestation with a minimum of 3 live head lice and at least\n             10 undamaged and unhatched head lice eggs in their hair.\n\n          4. Agrees to an examination for head lice and compliance with the study procedures.\n\n          5. All adult subjects must sign a written voluntary informed consent.  For minors, the\n             parent/ legal guardian agrees to the subject participating in the study as determined\n             by the signing of an assent of informed consent.\n\n        Exclusion Criteria:\n\n          1. Has scalp disease or a history of allergies or prior reactions to any head lice\n             products.\n\n          2. Has a condition that, in the opinion of the Investigator, may interfere with the\n             study.\n\n          3. Is receiving systemic or topical medication, which in the opinion of the\n             Investigator, may compromise the integrity of the safety and/or efficacy assessments.\n\n          4. Had treatment (over-the-counter (OTC) or home remedy medication) for head lice within\n             14 days prior to Day 0.\n\n          5. Has received an investigational agent within 30 days prior to Day 0."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "6 Months"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 24, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02097485", 
            "org_study_id": "Ha03-008"
        }, 
        "intervention": [
            {
                "arm_group_label": "Abametapir Lotion 0.74% w/w", 
                "description": "200mL abametapir lotion topically administered to the scalp and hair and once fully saturated left for 10 minutes and then washed out thoroughly with warm water.", 
                "intervention_name": "Abametapir Lotion 0.74% w/w", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Vehicle Lotion", 
                "description": "control to abametapir: 200mL Vehicle Lotion topically administered to the scalp and hair and once fully saturated left for 10 minutes and then washed out thoroughly with warm water.", 
                "intervention_name": "Vehicle Lotion", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "March 27, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Ringwood East", 
                    "country": "Australia", 
                    "state": "Victoria", 
                    "zip": "3135"
                }, 
                "name": "National Head Lice Treatment Centre"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Australia"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomised, Double-Blind, Vehicle-Controlled Study of Ovicidal Efficacy and Safety of Abametapir 0.74% Administered for the Treatment of Head Lice Infestation", 
        "overall_contact": {
            "email": "irondoc@bigpond.com", 
            "last_name": "Scott Arnold, MBBS"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Australia: Therapeutic Goods Administration"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Proportion of hatched eggs pre treatment relative to proportion of hatched eggs post treatment for the abametapir and vehicle treated eggs following 14 day incubation.", 
            "safety_issue": "No", 
            "time_frame": "14 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02097485"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Hatchtech Pty Ltd", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hatchtech Pty Ltd", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}